WORTHINGTON, Minn. (Sept. 4, 2018) — Newport Laboratories, Inc., a leader in livestock custom-made vaccines (CMVs), today launches HerdPoint,™ a new solution for veterinarians that streamlines the nonadjacent-herd approval process and ongoing isolate management, all from a mobile phone or computer.
DULUTH, Ga. — [June 12, 2018]
Boehringer Ingelheim (BI) is excited to announce that Newport Laboratories, Inc. in Worthington, Minnesota, is officially part of Boehringer Ingelheim’s animal health business unit.
Newport Laboratories enhances the service and product offerings for BI customers. By providing cutting-edge diagnostics like whole genome sequencing, metagenomics, and bioinformatics, Newport Laboratories crafts custom, autogenous vaccines that target the specific viruses or bacteria causing disease in individual livestock operations.
WORTHINGTON, Minn. – Veterinarian Randy Shirbroun of Newport Laboratories Inc. addressed more than 200 bison producers regarding the pathology and prevention of diseases caused by Mycoplasma bovis. The producers had gathered for the 2016 National Bison Association Summer Conference held in June at Elk River, Minnesota. Shirbroun specializes in ruminant health issues including those seen in the American bison, which became the official U.S. national mammal in May.
Newport Laboratories, Inc. has developed a new multilocus sequence typing (MLST) technique for Mycoplasma bovis, a significant cause of disease in cattle. The new technology represents a major advancement over the previous diagnostic process and will provide increased resolution and a better assessment of genetic variation that may be associated with antigenic, or strain differences. This technological advancement utilizing molecular biology is yet another development to come from Newport Laboratories, Inc., a leader in cutting edge diagnostic technology and the manufacturer of autogenous, or custom-made vaccines. The new MLST technique evaluates 10 variable genes associated with specific Mycoplasma bovis virulence factors, including several of the variable surface proteins (VSPs).
WORTHINGTON, MN - Newport Laboratories is excited to announce the arrival of ParaSail®, the swine industry's first avirulent live, single-dose vaccine for Haemophilus parasuis.
Available exclusively through veterinarians, ParaSail has been proven to protect against three of the most predominant strains of H. parasuis currently circulating: serotype 4 (found in 25% of cases), serotype 5 (found in 15% of all cases) and serotype 13. Multiple side-by-side comparisons have showed a single dose of the vaccine to be as effective as a two-dose regime. The USDA has approved ParaSail for use as a single-dose product with a 1mL dose size, intramuscular.
